BLLN
HealthcareBillionToOne, Inc. · Medical - Diagnostics & Research · $4B
What is BillionToOne, Inc.?
BillionToOne is a precision diagnostics company headquartered in Menlo Park, California, focused on quantifying biology at the molecular level. Its platform detects and measures individual DNA molecules to improve disease detection across prenatal screening and oncology.
BillionToOne develops and commercializes molecular diagnostics built on a proprietary molecular counting platform. The platform is engineered to detect DNA molecules at the single-count level, enabling high-sensitivity screening. Revenue is generated through laboratory testing services, with products spanning non-invasive prenatal testing and liquid biopsy for cancer monitoring. Clinicians use BillionToOne's tests to assess fetal chromosomal risk, identify tumor mutations, and track cancer burden over time — all from a blood draw rather than invasive procedures.
BillionToOne was incorporated in 2016 and is headquartered in Menlo Park, California.
- UNITY Complete — non-invasive prenatal screen from a maternal blood draw
- Northstar Select — liquid biopsy identifying tumor mutations including deletions and insertions
- Northstar Response — longitudinal cancer burden monitoring via methylation assessment
- Molecular counting platform for single-count DNA detection
Is BLLN a Good Stock to Buy?
UQS Score rates BLLN as Good overall, reflecting a mixed but forward-looking profile in the precision diagnostics space.
The strongest pillars for BLLN are Growth and Risk. The Growth pillar reflects the company's expanding footprint in high-demand areas like prenatal screening and liquid biopsy oncology testing. The Risk pillar suggests the business carries a relatively manageable risk profile relative to early-stage diagnostics peers.
Quality and Moat are both rated Weak, pointing to limited profitability durability and a competitive advantage that has yet to solidify at scale. Valuation is rated Elevated, meaning the market is pricing in significant future execution.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BLLN pay dividends?
No — BillionToOne, Inc. does not currently pay a dividend.
BillionToOne does not currently pay a dividend. As a growth-stage diagnostics company, capital is directed toward expanding its molecular platform, scaling commercial operations, and developing new test offerings. Investors in BLLN are typically focused on long-term revenue growth rather than near-term income distributions.
When does BLLN report earnings?
BillionToOne reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar rating suggests revenue momentum has been a relative bright spot, driven by adoption of its prenatal and oncology testing products. Quality metrics remain a work in progress, which is common for diagnostics companies still scaling toward profitability.
For the most recent quarter's results and guidance, visit BillionToOne's investor relations page directly.
BLLN Price History
-31.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
BLLN Long-term Outlook
BillionToOne's fundamental outlook is shaped by a Strong Growth pillar and a Strong Risk pillar, suggesting the business is expanding from a relatively stable base. The Elevated Valuation pillar indicates the market has priced in continued execution on that growth trajectory. Weak Quality and Moat ratings are the key variables — if the company can convert growth into durable margins and deepen its competitive position, the long-term profile could strengthen materially.
Growth drivers
- Expanding clinical adoption of UNITY Complete in prenatal screening
- Growing liquid biopsy market for oncology monitoring and mutation profiling
- Potential for platform extensions into additional disease areas
Key risks
- Weak Moat rating signals vulnerability to competition from larger diagnostics players
- Elevated Valuation leaves limited margin for execution shortfalls
- Weak Quality pillar reflects ongoing profitability challenges typical of scaling diagnostics companies
BLLN vs Peers
BillionToOne operates in a diagnostics landscape that includes companies spanning genomics, oncology services, and imaging — each with a distinct business model.
Twist focuses on synthetic DNA manufacturing and genomics tools rather than clinical diagnostic testing services.
Sotera Health provides sterilization and lab testing services to the broader healthcare supply chain, not molecular diagnostics.
RadNet operates outpatient imaging centers, competing in diagnostic services but through radiology rather than molecular or genomic testing.
Frequently Asked Questions
What does BillionToOne do?
BillionToOne is a precision diagnostics company that uses a molecular counting platform to detect and measure DNA at the single-molecule level. Its tests cover non-invasive prenatal screening and liquid biopsy for cancer, all performed from a blood draw. The company serves clinicians who need high-sensitivity molecular data without invasive procedures.
Does BLLN pay dividends?
BLLN does not pay a dividend. The company is in a growth phase and reinvests available capital into expanding its diagnostic platform and commercial reach. Investors drawn to BLLN are generally seeking capital appreciation rather than dividend income.
When does BLLN report earnings?
BillionToOne follows a standard quarterly earnings cadence for US-listed companies. For exact dates and the most recent financial results, check BillionToOne's investor relations page, as our data source does not cover forward earnings dates.
Is BLLN a good stock to buy?
UQS Score rates BLLN as Good overall. The Growth and Risk pillars are rated Strong, which is encouraging. However, Weak Quality and Moat ratings alongside an Elevated Valuation mean the investment case depends heavily on continued execution. The full pillar breakdown is available to Pro members.
Is BLLN overvalued?
BLLN carries an Elevated Valuation rating within the UQS framework, meaning the current price reflects high expectations for future growth. Whether that premium is justified depends on how quickly the company can improve its Quality and Moat profiles. View the complete valuation analysis with a Pro account.
How does BLLN compare to its competitors?
BillionToOne's closest listed peers include Twist Bioscience, Sotera Health, and RadNet — each operating in adjacent parts of the diagnostics and life sciences space. BLLN differentiates through its molecular counting technology and focus on prenatal and oncology liquid biopsy. Detailed UQS comparisons are available on each competitor's page.
What is BLLN's market cap bracket?
BLLN is classified as a mid-cap company. This places it in a tier where institutional coverage is growing but the stock may carry more volatility than large-cap diagnostics peers. Mid-cap diagnostics companies often balance meaningful revenue scale with continued investment in platform expansion.
Who founded BillionToOne?
BillionToOne was incorporated in 2016. Founding details are publicly available through the company's official communications and investor relations materials, which provide the most accurate and up-to-date background on its leadership history.
Is BLLN a long-term quality investment?
From a long-term quality perspective, BLLN's Strong Growth pillar is a positive signal, but Weak Quality and Moat ratings indicate the company has not yet built the durable competitive advantages that typically define high-quality long-term holdings. Tracking improvement in those pillars over time is key. The full UQS trend analysis is available to Pro members.
What is the main competitive advantage of BillionToOne?
BillionToOne's core differentiator is its molecular counting platform, which is designed to detect DNA at the single-count level — a level of sensitivity that supports both prenatal risk assessment and cancer monitoring. However, the UQS Moat pillar is currently rated Weak, suggesting this advantage has not yet translated into a clearly defensible market position.
What sector does BLLN belong to?
BLLN operates in the Healthcare sector, specifically within precision diagnostics and molecular testing. The company sits at the intersection of genomics and clinical laboratory services, targeting both reproductive health and oncology markets. You can explore other [top Healthcare stocks](/sector/healthcare) rated by UQS Score.
Is BLLN a growth stock or value stock?
Based on its UQS profile, BLLN leans firmly toward the growth category. Its Growth pillar is rated Strong while its Valuation pillar is Elevated — a combination typical of companies where the market is pricing in future expansion rather than current earnings power.
Unlock Full BLLN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and quality indicators
- ✓Compare BLLN against sector peers side by side
- ✓Track pillar changes across reporting periods
- ✓View the complete risk and valuation breakdown
- ✓Get Pro-level screening across thousands of tickers
Pro Analysis
BLLN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 51.2 | 35.4 | 28.0 | 80.0 | 100.0 | 29.0 | 0.0 |
| May 20, 2026 | 51.2 | 35.4 | 28.0 | 80.0 | 100.0 | 29.1 | 0.0 |
| May 19, 2026 | 51.2 | 35.4 | 28.0 | 80.0 | 100.0 | 29.0 | 0.0 |
| May 16, 2026 | 51.2 | 35.4 | 28.0 | 80.0 | 100.0 | 29.1 | 0.0 |
| May 14, 2026 | 51.2 | 35.4 | 28.0 | 80.0 | 100.0 | 28.8 | +0.1 |
| May 13, 2026 | 51.1 | 35.4 | 28.0 | 80.0 | 100.0 | 28.6 | 0.0 |
| May 12, 2026 | 51.1 | 35.4 | 28.0 | 80.0 | 100.0 | 28.2 | 0.0 |
| May 11, 2026 | 51.1 | 35.4 | 28.0 | 80.0 | 100.0 | 28.7 | +0.9 |
| May 10, 2026 | 50.2 | 25.9 | 28.0 | 80.0 | 100.0 | 38.2 | +2.8 |
| May 8, 2026 | 47.4 | 20.9 | 28.0 | 80.0 | 100.0 | 27.9 | -0.1 |
BLLN — Pillar Breakdown
Quality
— 35.4/100 (25%)BillionToOne, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 80.0/100 (20%)BillionToOne, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)BillionToOne, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 29.0/100 (15%)BillionToOne, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 28/100 (25%)BillionToOne, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BLLN.
Score Composition
Financial Data
More Stock Analysis
How is the BLLN UQS Score Calculated?
The UQS (Unified Quality Score) for BillionToOne, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BillionToOne, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BillionToOne, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.